Michael W. Beresford
University of Liverpool
248 Papers
686 Citations
Michael W. Beresford is an academic researcher from University of Liverpool. The author has contributed to research in topics: Medicine & Lupus nephritis. The author has an hindex of 39, co-authored 231 publications. Previous affiliations of Michael W. Beresford include Boston Children's Hospital & University of Manchester.
Chat about Author
Papers
Autoantibodies in juvenile-onset myositis: Their diagnostic value and associated clinical phenotype in a large UK cohort.
Sarah L Tansley,Sarah L Tansley,Stefania Simou,Gavin Shaddick,Zoe E Betteridge,Beverley Almeida,Harsha Gunawardena,Wendy Thomson,Michael W. Beresford,Angela Midgley,Francesco Muntoni,Lucy R. Wedderburn,Neil McHugh +12 more
TL;DR: There is evidence of a differential treatment approach and patients with anti-TIF1γ autoantibodies are significantly more likely to receive aggressive treatment with IV cyclophosphamide and/or biologic drugs, clear trends are also visible in otherAutoantibody subgroups.
161
Validity of a three-variable Juvenile Arthritis Disease Activity Score in children with new-onset juvenile idiopathic arthritis
Flora McErlane,Michael W. Beresford,Michael W. Beresford,Eileen Baildam,S.E. Alice Chieng,Joyce Davidson,Helen E. Foster,Janet Gardner-Medwin,Mark Lunt,Lucy R. Wedderburn,Wendy Thomson,Kimme L. Hyrich +11 more
TL;DR: This study is the first to apply JADAS to all categories of JIA in a routine clinical setting in the UK, adding further information about the feasibility and construct validity of JAD as well as exploring whether exclusion of the ESR influences correlation with single markers of disease activity.
153
European consensus-based recommendations for the diagnosis and treatment of Kawasaki disease – the SHARE initiative
Nienke de Graeff,Noortje Groot,Seza Ozen,Despina Eleftheriou,Tadej Avcin,Brigitte Bader-Meunier,Pavla Dolezalova,Brian M. Feldman,Isabelle Koné-Paut,Pekka Lahdenne,Liza J McCann,Clarissa Pilkington,Angelo Ravelli,Annet van Royen-Kerkhof,Yosef Uziel,Bas Vastert,Nico M Wulffraat,Sylvia Kamphuis,Paul A. Brogan,Michael W. Beresford +19 more
TL;DR: The Single Hub and Access point for paediatric Rheumatology in Europe initiative provides international evidence-based recommendations for diagnosing and treating Kawasaki disease in children, facilitating improvement and uniformity of care.
European evidence-based recommendations for the diagnosis and treatment of childhood-onset lupus nephritis: the SHARE initiative
Noortje Groot,Noortje Groot,Nienke de Graeff,Stephen D. Marks,Paul A. Brogan,Tadej Avcin,Brigitte Bader-Meunier,Pavla Dolezalova,Brian M. Feldman,Isabelle Koné-Paut,Pekka Lahdenne,Liza J McCann,Seza Ozen,Clarissa Pilkington,Angelo Ravelli,Annet van Royen-Kerkhof,Yosef Uziel,Bas Vastert,Nico M Wulffraat,Michael W. Beresford,Sylvia Kamphuis +20 more
TL;DR: Evidence-based recommendations for diagnosis and treatment of childhood lupus nephritis have been generated to support uniform and high-quality care for all children with SLE.
A randomised controlled trial of the clinical effectiveness, safety and cost-effectiveness of adalimumab in combination with methotrexate for the treatment of juvenile idiopathic arthritis associated uveitis (SYCAMORE Trial)
Athimalaipet V Ramanan,Andrew D. Dick,Diana Benton,Sandrine Compeyrot-Lacassagne,Dalia Dawoud,Ben Hardwick,Helen Hickey,Dyfrig A. Hughes,Ashley P Jones,Patricia Woo,Clive Edelsten,Michael W. Beresford +11 more
TL;DR: This is the first randomised controlled trial that will assess the clinical effectiveness, safety and cost effectiveness of adalimumab in combination with methotrexate for the treatment of juvenile idiopathic arthritis associated uveitis.